Universal Beteiligungs und Servicegesellschaft mbH Decreases Position in Elevance Health, Inc. $ELV

Universal Beteiligungs und Servicegesellschaft mbH lowered its stake in shares of Elevance Health, Inc. (NYSE:ELV) by 11.4% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 280,378 shares of the company’s stock after selling 35,973 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.13% of Elevance Health worth $90,596,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of the stock. U.S. Capital Wealth Advisors LLC boosted its stake in Elevance Health by 11.3% during the 2nd quarter. U.S. Capital Wealth Advisors LLC now owns 589 shares of the company’s stock worth $229,000 after purchasing an additional 60 shares during the period. Golden State Equity Partners grew its holdings in shares of Elevance Health by 20.4% during the second quarter. Golden State Equity Partners now owns 1,226 shares of the company’s stock worth $477,000 after buying an additional 208 shares during the last quarter. Leonard Rickey Investment Advisors P.L.L.C. grew its holdings in shares of Elevance Health by 6.9% during the second quarter. Leonard Rickey Investment Advisors P.L.L.C. now owns 1,267 shares of the company’s stock worth $493,000 after buying an additional 82 shares during the last quarter. Opal Wealth Advisors LLC increased its position in Elevance Health by 579.2% in the 2nd quarter. Opal Wealth Advisors LLC now owns 360 shares of the company’s stock valued at $140,000 after acquiring an additional 307 shares during the period. Finally, Steigerwald Gordon & Koch Inc. raised its stake in Elevance Health by 2.4% during the 2nd quarter. Steigerwald Gordon & Koch Inc. now owns 45,598 shares of the company’s stock valued at $17,736,000 after acquiring an additional 1,054 shares during the last quarter. Institutional investors and hedge funds own 89.24% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently commented on ELV. Zacks Research upgraded shares of Elevance Health from a “strong sell” rating to a “hold” rating in a research report on Thursday, November 6th. Bank of America lifted their price target on Elevance Health from $330.00 to $370.00 and gave the company a “neutral” rating in a research note on Friday, October 10th. Cowen reiterated a “buy” rating on shares of Elevance Health in a research report on Wednesday, November 26th. Wall Street Zen downgraded Elevance Health from a “buy” rating to a “hold” rating in a report on Saturday, December 13th. Finally, Robert W. Baird boosted their target price on shares of Elevance Health from $297.00 to $340.00 and gave the stock a “neutral” rating in a research report on Thursday, December 11th. Thirteen investment analysts have rated the stock with a Buy rating and twelve have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Elevance Health presently has a consensus rating of “Moderate Buy” and an average price target of $400.85.

Elevance Health Stock Down 2.2%

Shares of NYSE:ELV opened at $366.62 on Wednesday. The company has a current ratio of 1.56, a quick ratio of 1.56 and a debt-to-equity ratio of 0.71. The firm has a market cap of $81.48 billion, a price-to-earnings ratio of 14.99, a PEG ratio of 1.93 and a beta of 0.51. The stock’s 50-day moving average price is $346.57 and its two-hundred day moving average price is $328.18. Elevance Health, Inc. has a 12-month low of $273.71 and a 12-month high of $458.75.

Elevance Health (NYSE:ELV) last posted its quarterly earnings results on Tuesday, October 21st. The company reported $6.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.03 by $1.00. The firm had revenue of $50.09 billion during the quarter, compared to the consensus estimate of $49.26 billion. Elevance Health had a return on equity of 16.17% and a net margin of 2.84%.The firm’s quarterly revenue was up 12.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $8.37 earnings per share. On average, research analysts forecast that Elevance Health, Inc. will post 33.96 EPS for the current year.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.